Business

Genzyme encouraged by MS drug

Genzyme, a Cambridge unit of French drug maker Sanofi SA, reported the publication of encouraging results from studies of Lemtrada, its drug candidate for treating multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is being reviewed by European regulators. At some point, Genzyme plans to seek Food and Drug Administration approval.

Advertisement

The studies published in Lancet were chaired by Alastair Compston, a professor of neurology at the UK’s University of Cambridge. A quote from Compston was included in the Genzyme press release.

Lemtrada has the potential to “become a transformative therapy amongst the various MS treatment options that are currently available,” he said.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

In a statement, Genzyme chief executive David Meeker added: “Genzyme set a new standard by comparing Lemtrada exclusively to an approved treatment in all of our studies. Publication of these findings by the Lancet highlights the importance of these results to the MS community.”

Chris Reidy

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com